

Jesus San Miguel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6789920/publications.pdf>

Version: 2024-02-01

1,068
papers

92,194
citations

336

137
h-index

517

267
g-index

1088
all docs

1088
docs citations

1088
times ranked

36997
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
2	International Staging System for Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 3412-3420.	1.6	2,404
3	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	27.0	2,356
4	Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 2003, 121, 749-757.	2.5	1,887
5	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
6	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 2008, 359, 906-917.	27.0	1,787
7	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	1.6	1,525
8	Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2007, 357, 2123-2132.	27.0	1,365
9	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	27.8	1,364
10	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 1319-1331.	27.0	1,210
11	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2015, 372, 142-152.	27.0	1,144
12	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2015, 373, 621-631.	27.0	1,139
13	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021, 384, 705-716.	27.0	1,129
14	Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia, 1999, 13, 1901-1928.	7.2	1,038
15	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	1.4	849
16	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 110-115.	2.2	841
17	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, 22, 414-423.	7.2	787
18	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine, 2018, 378, 518-528.	27.0	747

#	ARTICLE	IF	CITATIONS
19	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1055-1066.	10.7	710
20	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
21	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. <i>Leukemia</i> , 2009, 23, 215-224.	7.2	686
22	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	1.4	686
23	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 1192-1200.	1.4	682
24	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. <i>Leukemia</i> , 2010, 24, 1121-1127.	7.2	677
25	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
26	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.	1.2	619
27	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. <i>Journal of Clinical Oncology</i> , 2007, 25, 3892-3901.	1.6	607
28	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
29	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
30	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
31	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. <i>Leukemia</i> , 2017, 31, 2094-2103.	7.2	486
32	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007, 110, 3557-3560.	1.4	485
33	Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. <i>New England Journal of Medicine</i> , 2013, 369, 438-447.	27.0	449
34	New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. <i>Blood</i> , 2007, 110, 2586-2592.	1.4	447
35	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.	1.4	438
36	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 2096-2107.	13.7	435

#	ARTICLE	IF	CITATIONS
37	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	1.4	429
38	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. <i>Leukemia</i> , 2009, 23, 1545-1556.	7.2	428
39	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 934-941.	10.7	427
40	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood</i> , 2008, 112, 4017-4023.	1.4	425
41	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	27.0	413
42	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.	1.6	403
43	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	10.7	394
44	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.	1.4	380
45	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	1.4	377
46	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-398.	1.4	374
47	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. <i>Blood</i> , 2006, 108, 2165-2172.	1.4	373
48	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	1.6	358
49	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018, 132, 587-597.	1.4	335
50	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
51	Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia. <i>Leukemia</i> , 1999, 13, 110-118.	7.2	328
52	Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. <i>Blood</i> , 2001, 98, 1746-1751.	1.4	316
53	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 309-322.	1.2	316
54	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.	7.2	313

#	ARTICLE	IF	CITATIONS
55	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	1.4	309
56	1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. <i>Leukemia Research</i> , 1983, 7, 51-55.	0.8	308
57	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 132-141.	13.7	299
58	High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. <i>Blood</i> , 2005, 106, 3755-3759.	1.4	298
59	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. <i>Leukemia</i> , 2013, 27, 780-791.	7.2	294
60	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	1.6	294
61	Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. <i>British Journal of Haematology</i> , 2003, 122, 394-403.	2.5	292
62	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	27.0	291
63	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , The, 2019, 20, e302-e312.	10.7	290
64	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.	2.5	289
65	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
66	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	1.4	282
67	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.	1.4	278
68	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	1.4	274
69	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5775-5782.	1.6	263
70	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	10.7	254
71	Intracлона heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. <i>Leukemia</i> , 2014, 28, 384-390.	7.2	252
72	Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. <i>Cancer Cell</i> , 2017, 31, 396-410.	16.8	251

#	ARTICLE	IF	CITATIONS
73	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 448-455.	1.6	250
74	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	1.6	248
75	A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , 2008, 112, 3591-3593.	1.4	247
76	The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. <i>Haematologica</i> , 2008, 93, 1301-1309.	3.5	243
77	Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients. <i>Blood</i> , 1997, 90, 2465-2470.	1.4	241
78	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. <i>Haematologica</i> , 2010, 95, 589-596.	3.5	240
79	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <i>Leukemia</i> , 2013, 27, 1722-1728.	7.2	238
80	Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. <i>Blood</i> , 2002, 100, 3121-3127.	1.4	236
81	The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. <i>Cancer Research</i> , 2006, 66, 5781-5789.	0.9	233
82	Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. <i>British Journal of Haematology</i> , 2001, 115, 575-582.	2.5	222
83	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 728-734.	1.6	221
84	Minimal residual disease in leukaemia patients. <i>Lancet Oncology</i> , The, 2001, 2, 409-417.	10.7	217
85	Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012, 26, 595-608.	7.2	217
86	Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. <i>Blood</i> , 2008, 112, 2709-2712.	1.4	213
87	Therapy-Related Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 2123-2137.	1.6	212
88	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4767-4773.	7.0	212
89	Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. <i>British Journal of Haematology</i> , 2001, 113, 1020-1034.	2.5	207
90	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). <i>Leukemia</i> , 2009, 23, 1904-1912.	7.2	207

#	ARTICLE	IF	CITATIONS
91	Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. <i>Leukemia</i> , 1999, 13, 419-427.	7.2	205
92	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016, 30, 1005-1017.	7.2	204
93	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. <i>Blood</i> , 2009, 114, 1729-1735.	1.4	203
94	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1627-1633.	1.6	202
95	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. <i>Annals of Oncology</i> , 2009, 20, 1303-1317.	1.2	201
96	Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. <i>Blood</i> , 2010, 115, 107-121.	1.4	201
97	Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 2737-2744.	1.6	193
98	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	3.5	193
99	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 1049 patients from the International Myeloma Working Group. <i>Blood</i> , 2008, 111, 4039-4047.	1.4	190
100	Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. <i>Blood</i> , 2006, 107, 3575-3583.	1.4	188
101	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. <i>Leukemia</i> , 2010, 24, 629-637.	7.2	188
102	Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. <i>Leukemia</i> , 2007, 21, 541-549.	7.2	187
103	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. <i>Lancet Oncology</i> , 2010, 11, 1086-1095.	10.7	187
104	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi133-vi137.	1.2	187
105	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. <i>Blood</i> , 2014, 123, 4120-4131.	1.4	187
106	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018, 103, 2088-2096.	3.5	187
107	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , 2019, 393, 253-264.	13.7	187
108	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	1.4	183

#	ARTICLE	IF	CITATIONS
109	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.	30.7	179
110	Isolation and Characterization of Mesenchymal Stromal Cells From Human Degenerated Nucleus Pulposus. <i>Spine</i> , 2010, 35, 2259-2265.	2.0	178
111	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	1.4	178
112	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	1.6	175
113	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e459-e469.	4.6	174
114	PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. <i>Leukemia</i> , 2015, 29, 2110-2113.	7.2	170
115	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
116	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e448-e458.	4.6	168
117	Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. <i>Blood</i> , 2002, 100, 2243-2245.	1.4	167
118	Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. <i>Leukemia</i> , 2007, 21, 143-150.	7.2	167
119	Immunophenotypic analysis of Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 187-195.	2.2	165
120	Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. <i>Leukemia</i> , 2008, 22, 842-849.	7.2	163
121	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , 2020, 34, 1875-1884.	7.2	163
122	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014, 28, 981-992.	7.2	162
123	The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2004, 18, 856-863.	7.2	157
124	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. <i>Blood</i> , 2007, 110, 3112-3121.	1.4	157
125	International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4521-4530.	1.6	156
126	The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3176-3187.	7.0	156

#	ARTICLE	IF	CITATIONS
127	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.	1.6	154
128	Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. <i>Blood</i> , 2013, 121, 884-892.	1.4	153
129	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.	1.6	150
130	Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. <i>Blood</i> , 2012, 120, 2581-2588.	1.4	148
131	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i> , 2019, 134, 1337-1345.	1.4	148
132	Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1998, 16, 3774-3781.	1.6	147
133	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood And Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
134	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	1.4	146
135	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	3.5	144
136	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	1.4	144
137	Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. <i>Experimental Hematology</i> , 2008, 36, 1014-1021.	0.4	143
138	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1599-1605.	1.6	142
139	Chronic T cell lymphocytosis: a review of 21 cases. <i>British Journal of Haematology</i> , 1984, 58, 433-446.	2.5	140
140	Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. <i>Blood</i> , 2002, 99, 1853-1856.	1.4	140
141	Teclistamab, a B-cell maturation antigen-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet, The</i> , 2021, 398, 665-674.	13.7	138
142	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1716-1730.	7.2	136
143	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.	10.7	136
144	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005, 90, 1365-72.	3.5	135

#	ARTICLE	IF	CITATIONS
145	BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplantation, 1997, 20, 451-458.	2.4	134
146	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica, 2013, 98, 79-86.	3.5	132
147	Outcome of Childhood Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid and Chemotherapy. Journal of Clinical Oncology, 2004, 22, 1404-1412.	1.6	131
148	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood, 2013, 122, 3591-3598.	1.4	131
149	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood, 2009, 114, 1166-1173.	1.4	129
150	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	1.4	129
151	BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. Leukemia, 2001, 15, 1185-1192.	7.2	128
152	The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Clinical Cancer Research, 2011, 17, 1692-1700.	7.0	128
153	Lenalidomide plus dexamethasone versus observation in patients with high-risk smoldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1127-1136.	10.7	128
154	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. British Journal of Haematology, 2000, 111, 801-806.	2.5	127
155	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Blood, 2019, 134, 143-143.	1.4	127
156	Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood, 2003, 101, 4695-4700.	1.4	126
157	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal of Haematology, 2011, 86, 23-31.	2.2	126
158	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal, 2020, 10, 102.	6.2	126
159	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood, 2014, 123, 4136-4142.	1.4	125
160	Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11qâ~ and 17pâ~). Clinical Cancer Research, 2005, 11, 7757-7763.	7.0	124
161	Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia, 2007, 21, 446-452.	7.2	124
162	Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5qâ~ syndrome. Leukemia, 2009, 23, 664-672.	7.2	124

#	ARTICLE	IF	CITATIONS
163	Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3696-3703.	1.6	123
164	Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All- <i>trans</i> -Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 120-126.	1.6	122
165	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009, 114, 5436-5443.	1.4	122
166	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	1.4	121
167	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e506-e515.	4.6	121
168	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <i>ELOQUENT-2</i> follow-up and <i>post-hoc</i> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	2.5	120
169	Whole-genome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. <i>Genome Research</i> , 2015, 25, 478-487.	5.5	118
170	New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. <i>Lancet Oncology</i> , 2008, 9, 1157-1165.	10.7	116
171	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 429-435.	2.5	115
172	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	1.6	115
173	Expression of the c-kit (CD117) Molecule in Normal and Malignant Hematopoiesis. <i>Leukemia and Lymphoma</i> , 1998, 30, 459-466.	1.3	113
174	Immunophenotypic Analysis of the TCR-V β 2 Repertoire in 98 Persistent Expansions of CD3+/TCR- β ⁺ Large Granular Lymphocytes. <i>American Journal of Pathology</i> , 2001, 159, 1861-1868.	3.8	113
175	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. <i>Leukemia</i> , 2013, 27, 430-440.	7.2	112
176	High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 1999, 107, 121-131.	2.5	110
177	Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. <i>British Journal of Haematology</i> , 2005, 130, 394-403.	2.5	110
178	Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2005, 11, 3661-3667.	7.0	109
179	6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , 2007, 136, 80-86.	2.5	109
180	Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 239-252.	1.5	109

#	ARTICLE	IF	CITATIONS
181	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	7.2	109
182	Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. <i>British Journal of Haematology</i> , 1986, 64, 547-560.	2.5	108
183	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. <i>Leukemia</i> , 2011, 25, 749-760.	7.2	108
184	Cell Surface Markers in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 1994, 69, 684-690.	3.0	107
185	Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. <i>Leukemia</i> , 2002, 16, 1460-1469.	7.2	107
186	Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics. <i>Journal of Clinical Oncology</i> , 2007, 25, 4452-4458.	1.6	106
187	Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. <i>Investigational New Drugs</i> , 2012, 30, 1121-1131.	2.6	105
188	BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia</i> , 2000, 14, 816-825.	7.2	104
189	TCR β +/CD4+ Large Granular Lymphocytosis. <i>American Journal of Pathology</i> , 2003, 163, 763-771.	3.8	104
190	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2009, 82, 426-432.	2.2	104
191	Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. <i>The Hematology Journal</i> , 2000, 1, 28-36.	1.4	104
192	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. <i>Leukemia</i> , 2002, 16, 1423-1431.	7.2	103
193	Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 698-708.	2.0	103
194	Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. <i>Annals of Oncology</i> , 2000, 11, 441-444.	1.2	102
195	Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. <i>British Journal of Haematology</i> , 2001, 115, 653-659.	2.5	102
196	A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma. <i>Oncologist</i> , 2006, 11, 51-61.	3.7	102
197	Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. <i>British Journal of Haematology</i> , 2010, 148, 110-114.	2.5	102
198	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017, 28, 228-245.	1.2	102

#	ARTICLE	IF	CITATIONS
199	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. <i>Blood</i> , 2003, 102, 2994-3002.	1.4	101
200	Busulfan 12 mg/kg plus melphalan 140 mg/m ² versus melphalan 200 mg/m ² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	3.5	101
201	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	1.4	101
202	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 438-446.	2.5	100
203	Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003, 102, 1108-1113.	1.4	100
204	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. <i>Leukemia</i> , 2012, 26, 2521-2529.	7.2	100
205	Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. <i>Hepatology</i> , 1997, 25, 1096-1100.	7.3	99
206	Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006, 37, 1135-1141.	2.4	98
207	Aplidin, a Marine Organismâ€™Derived Compound with Potent Antimyeloma Activity <i>In vitro</i> and <i>In vivo</i>. <i>Cancer Research</i> , 2008, 68, 5216-5225.	0.9	98
208	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014, 123, 632-639.	1.4	98
209	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	7.2	98
210	Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010, 150, 28-38.	2.5	95
211	GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. <i>Blood</i> , 2014, 124, 1887-1893.	1.4	95
212	Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. <i>British Journal of Haematology</i> , 1991, 77, 185-190.	2.5	94
213	Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. <i>Leukemia</i> , 2001, 15, 406-414.	7.2	94
214	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019, 133, 1953-1963.	1.4	94
215	Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. <i>Blood</i> , 2004, 103, 4056-4061.	1.4	93
216	Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. <i>Blood</i> , 2004, 104, 2661-2666.	1.4	92

#	ARTICLE	IF	CITATIONS
217	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. <i>Haematologica</i> , 2009, 94, 1599-1602.	3.5	92
218	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017, 19, 218-224.	6.4	92
219	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e119-e130.	10.7	92
220	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 222-229.	2.5	91
221	Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. <i>Haematologica</i> , 2003, 88, 555-60.	3.5	91
222	Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>British Journal of Haematology</i> , 2003, 121, 104-108.	2.5	90
223	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
224	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	1.4	90
225	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.	6.2	90
226	Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. <i>Haematologica</i> , 2004, 89, 58-69.	3.5	90
227	Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. <i>American Journal of Pathology</i> , 2001, 158, 1843-1850.	3.8	88
228	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 668-677.	1.4	87
229	TCR β ^{hi} large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCR β ^{hi} T-cells. <i>Leukemia</i> , 2006, 20, 505-513.	7.2	86
230	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-98.	1.4	86
231	Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2167-2173.	1.6	85
232	Comparative Analysis of the Morphological, Cytochemical, Immunophenotypical, and Functional Characteristics of Normal Human Peripheral Blood Lineage α^+ /CD16+/HLA-DR+/CD14 α^+ /lo Cells, CD14+ Monocytes, and CD16 α^+ Dendritic Cells. <i>Clinical Immunology</i> , 2001, 100, 325-338.	3.2	85
233	Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 402-409.	7.2	85
234	Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1163-1171.	2.0	85

#	ARTICLE	IF	CITATIONS
235	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. <i>Oncologist</i> , 2010, 15, 6-25.	3.7	85
236	Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2001, 27, 511-515.	2.4	84
237	Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2001, 113, 161-171.	2.5	83
238	Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. <i>Leukemia</i> , 2005, 19, 449-455.	7.2	83
239	Veno-Occlusive Disease of the Liver after High-Dose Cytoablative Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1448-1454.	2.0	83
240	Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. <i>Haematologica</i> , 2012, 97, 1218-1224.	3.5	83
241	Differentiation stage of myeloma plasma cells: biological and clinical significance. <i>Leukemia</i> , 2017, 31, 382-392.	7.2	83
242	Multifunctional role of Erk5 in multiple myeloma. <i>Blood</i> , 2005, 105, 4492-4499.	1.4	82
243	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. <i>Haematologica</i> , 2008, 93, 560-565.	3.5	82
244	Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. <i>Leukemia</i> , 2006, 20, 542-545.	7.2	81
245	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016, 127, 1896-1906.	1.4	81
246	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma â€” an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018, 8, 123.	6.2	81
247	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	7.2	81
248	The cellular origin and malignant transformation of Waldenström macroglobulinemia. <i>Blood</i> , 2015, 125, 2370-2380.	1.4	80
249	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021, 137, 49-60.	1.4	80
250	Expression of the CD117 antigen (C-kit) on normal and myelomatous plasma cells. <i>British Journal of Haematology</i> , 1996, 95, 489-493.	2.5	79
251	Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. <i>Leukemia</i> , 2008, 22, 1250-1255.	7.2	79
252	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	7.2	79

#	ARTICLE	IF	CITATIONS
253	Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. <i>Transfusion</i> , 1998, 38, 385-391.	1.6	78
254	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , 2009, 113, 3781-3791.	1.4	78
255	Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2009, 114, 148-152.	1.4	78
256	Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1916-1923.	1.6	78
257	A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. <i>Leukemia</i> , 2013, 27, 2056-2061.	7.2	78
258	Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. <i>British Journal of Haematology</i> , 1990, 75, 26-33.	2.5	77
259	Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. <i>Bone Marrow Transplantation</i> , 1998, 21, 133-140.	2.4	77
260	Immunophenotyping of acute leukemias and myelodysplastic syndromes. , 2004, 58A, 62-71.		77
261	Using quantification of the PML-RAR α transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 315-322.	3.5	77
262	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan+prednisone vs. melphalan+prednisone in the phase III VISTA trial in multiple myeloma. <i>European Journal of Haematology</i> , 2011, 86, 372-384.	2.2	77
263	Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission. <i>Clinical Cancer Research</i> , 2013, 19, 4770-4779.	7.0	77
264	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. <i>British Journal of Haematology</i> , 2002, 118, 1034-1040.	2.5	76
265	Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. <i>Leukemia</i> , 2003, 17, 2016-2024.	7.2	76
266	Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents. <i>Journal of Clinical Oncology</i> , 2008, 26, 2761-2766.	1.6	76
267	The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. <i>Leukemia</i> , 2010, 24, 1700-1712.	7.2	76
268	Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. <i>Leukemia</i> , 2014, 28, 166-173.	7.2	76
269	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. <i>Leukemia</i> , 2016, 30, 526-535.	7.2	76
270	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	1.4	76

#	ARTICLE	IF	CITATIONS
271	Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Blood</i> , 2006, 107, 3415-3416.	1.4	75
272	Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. <i>Leukemia</i> , 2011, 25, 697-706.	7.2	75
273	Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. <i>Haematologica</i> , 2013, 98, 640-648.	3.5	75
274	Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease. <i>Clinical Cancer Research</i> , 2014, 20, 1542-1554.	7.0	75
275	Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 332-340.	4.7	75
276	Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. <i>British Journal of Haematology</i> , 1995, 90, 106-112.	2.5	74
277	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). <i>Blood Cancer Journal</i> , 2018, 8, 117.	6.2	74
278	Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2003, 31, 387-392.	2.4	73
279	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , 2012, 26, 1862-1869.	7.2	73
280	Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples. <i>Analytical Cellular Pathology</i> , 1998, 16, 151-159.	2.1	72
281	Conventional diagnostics in multiple myeloma. <i>European Journal of Cancer</i> , 2006, 42, 1510-1519.	2.8	72
282	Can multiple myeloma become a curable disease?. <i>Haematologica</i> , 2011, 96, 1246-1248.	3.5	72
283	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , 2015, 29, 705-714.	7.2	72
284	Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development. <i>Journal of Hematology and Oncology</i> , 2016, 9, 113.	17.0	72
285	Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. <i>Leukemia</i> , 2003, 17, 339-342.	7.2	71
286	Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. <i>British Journal of Haematology</i> , 2004, 127, 159-164.	2.5	71
287	Chronic Graft-Versus-Host Disease. <i>Drugs</i> , 2006, 66, 1041-1057.	10.9	71
288	Guidelines for determination of the number of prior lines of therapy in multiple myeloma. <i>Blood</i> , 2015, 126, 921-922.	1.4	71

#	ARTICLE	IF	CITATIONS
289	Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. <i>Leukemia</i> , 2015, 29, 1186-1194.	7.2	71
290	Bone Marrow Mesenchymal Stem Cell (BM-MSC) Release Microvesicles/Exosomes That Incorporate Into Hematopoietic Cells From MDS Patients and May Modify Their Behaviour. <i>Blood</i> , 2013, 122, 863-863.	1.4	71
291	Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. <i>British Journal of Haematology</i> , 1985, 59, 277-296.	2.5	70
292	Emerging therapies for the treatment of relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2011, 86, 1-15.	2.2	70
293	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
294	Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. <i>British Journal of Haematology</i> , 1996, 93, 81-88.	2.5	69
295	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. <i>British Journal of Haematology</i> , 2000, 109, 138-147.	2.5	69
296	Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. <i>Cancer Treatment Reviews</i> , 2005, 31, 591-602.	7.7	69
297	Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. <i>Haematologica</i> , 2013, 98, 437-443.	3.5	69
298	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	7.2	69
299	A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. <i>Cytometry</i> , 1994, 17, 332-339.	1.8	68
300	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. <i>Cancer</i> , 2008, 112, 1529-1537.	4.1	68
301	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	3.5	68
302	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.	1.4	68
303	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
304	Mechanical, chemical and biological damage modes within headâ€¦neck tapers of CoCrMo and Ti6Al4V contemporary hip replacements. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2018, 106, 1672-1685.	3.4	68
305	Weekly iron supplementation is as effective as 5 day per week iron supplementation in Bolivian school children living at high altitude. <i>European Journal of Clinical Nutrition</i> , 1997, 51, 381-386.	2.9	67
306	Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 1279-1283.	2.4	67

#	ARTICLE	IF	CITATIONS
307	Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. Journal of Clinical Investigation, 2005, 115, 2351-2362.	8.2	67
308	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood, 2009, 114, 4369-4372.	1.4	67
309	Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood, 2014, 124, 1300-1303.	1.4	67
310	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
311	Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. Blood, 2015, 126, 505-505.	1.4	67
312	Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. American Journal of Hematology, 2005, 78, 302-305.	4.1	66
313	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 2011, 37, 266-283.	7.7	66
314	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood, 2019, 134, 2218-2222.	1.4	66
315	Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 341-347.	2.4	65
316	The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia, 2008, 22, 1479-1484.	7.2	65
317	Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with <scp>VMP</scp> vs. <scp>MP</scp>: results from the <scp>VISTA</scp> trial. European Journal of Haematology, 2012, 89, 16-27.	2.2	65
318	Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica, 2014, 99, 1365-1372.	3.5	65
319	Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica, 2002, 87, 609-14.	3.5	65
320	Management of multiple myeloma in the newly diagnosed patient. Hematology American Society of Hematology Education Program, 2017, 2017, 498-507.	2.5	64
321	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood, 2022, 139, 492-501.	1.4	64
322	High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Annals of Oncology, 2003, 14, 140-151.	1.2	63
323	Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia, 2017, 31, 1922-1927.	7.2	63
324	¹¹ C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics, 2017, 7, 2956-2964.	10.0	63

#	ARTICLE	IF	CITATIONS
325	Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. <i>Cytometry</i> , 1997, 30, 98-102.	1.8	62
326	Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2010, 16, 3260-3269.	7.0	62
327	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, 192.	6.2	62
328	Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2007, 12, E336-40.	1.7	62
329	Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.. <i>Journal of Clinical Oncology</i> , 1993, 11, 1165-1171.	1.6	61
330	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	2.5	61
331	Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.. <i>Journal of Clinical Pathology</i> , 1996, 49, 15-18.	2.0	60
332	Clinicobiological, Immunophenotypic, and Molecular Characteristics of Monoclonal CD56 ⁺ /+dim Chronic Natural Killer Cell Large Granular Lymphocytosis. <i>American Journal of Pathology</i> , 2004, 165, 1117-1127.	3.8	60
333	Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 29-37.	1.3	60
334	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 69-74.	2.0	60
335	Treatment for High-Risk Smoldering Myeloma. <i>New England Journal of Medicine</i> , 2013, 369, 1762-1765.	27.0	60
336	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.	6.2	60
337	Bortezomib is an efficient agent in plasma cell leukemias. <i>International Journal of Cancer</i> , 2005, 114, 665-667.	5.1	59
338	A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. <i>Haematologica</i> , 2009, 94, 364-371.	3.5	59
339	Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. <i>Cytotherapy</i> , 2009, 11, 698-705.	0.7	59
340	Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 38-43.	0.4	59
341	The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. <i>Blood</i> , 2011, 117, 3613-3616.	1.4	59
342	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. <i>Blood Cancer Journal</i> , 2018, 8, 95.	6.2	59

#	ARTICLE	IF	CITATIONS
343	Minimal residual disease monitoring by flow cytometry. Best Practice and Research in Clinical Haematology, 2003, 16, 599-612.	1.7	58
344	Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a skewed TCR-V β repertoire. Cancer, 2006, 106, 1296-1305.	4.1	58
345	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia, 2009, 23, 2265-2274.	7.2	58
346	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. American Journal of Hematology, 2015, 90, 314-319.	4.1	58
347	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. British Journal of Haematology, 2017, 177, 404-413.	2.5	58
348	Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. British Journal of Haematology, 2019, 186, e117-e121.	2.5	58
349	Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica, 2007, 92, 635-642.	3.5	57
350	Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer Journal, 2020, 10, 103.	6.2	57
351	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Journal of Clinical Oncology, 2021, 39, 1139-1149.	1.6	57
352	De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia, 2000, 14, 183-187.	7.2	56
353	Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia, 2003, 17, 1124-1129.	7.2	56
354	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica, 2008, 93, 57-66.	3.5	56
355	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	1.4	56
356	Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia, 2005, 19, 713-720.	7.2	55
357	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. British Journal of Haematology, 2008, 143, 511-519.	2.5	55
358	Defining and treating high-risk multiple myeloma. Leukemia, 2015, 29, 2119-2125.	7.2	55
359	Immunophenotype and DNA cell content in multiple myeloma. Best Practice and Research: Clinical Haematology, 1995, 8, 735-759.	1.1	54
360	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. British Journal of Haematology, 2002, 118, 239-242.	2.5	54

#	ARTICLE	IF	CITATIONS
361	Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. <i>Leukemia</i> , 2004, 18, 491-498.	7.2	54
362	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 352-355.	1.4	54
363	Redefining myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 494-496.	27.6	54
364	Carfilzomib+“lenalidomide+“dexamethasone vs lenalidomide+“dexamethasone in relapsed multiple myeloma by previous treatment. <i>Blood Cancer Journal</i> , 2017, 7, e554-e554.	6.2	54
365	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 416-427.	10.7	54
366	Iron metabolism and fungal infections in patients with haematological malignancies.. <i>Journal of Clinical Pathology</i> , 1995, 48, 223-225.	2.0	53
367	Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: Comparative analysis of different stimuli, secretion-blocking agents and incubation periods. <i>Cytometry</i> , 2001, 46, 33-40.	1.8	53
368	Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. <i>British Journal of Haematology</i> , 2003, 123, 858-868.	2.5	53
369	Medium-term results of percutaneous vertebroplasty in multiple myeloma. <i>European Journal of Haematology</i> , 2006, 77, 7-13.	2.2	53
370	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. <i>Blood</i> , 2011, 118, 4547-4553.	1.4	53
371	How should we treat newly diagnosed multiple myeloma patients?. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 488-495.	2.5	53
372	Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. <i>British Journal of Haematology</i> , 1986, 62, 75-83.	2.5	51
373	Acute Lymphoblastic Leukemia (ALL): Detection of Minimal Residual Disease (MRD) at Flow Cytometry. <i>Leukemia and Lymphoma</i> , 1994, 13, 87-90.	1.3	51
374	Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. <i>Haematologica</i> , 2009, 94, 975-983.	3.5	51
375	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. <i>Blood</i> , 2016, 127, 420-425.	1.4	51
376	Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 27-27.	1.4	51
377	Prognostic factors and classification in multiple myeloma. <i>British Journal of Cancer</i> , 1989, 59, 113-118.	6.4	50
378	Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. , 1999, 60, 191-195.		50

#	ARTICLE	IF	CITATIONS
379	Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. <i>Leukemia</i> , 2001, 15, 840-845.	7.2	50
380	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. <i>Blood</i> , 2015, 126, 858-862.	1.4	50
381	Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. <i>Haematologica</i> , 2018, 103, e318-e321.	3.5	50
382	Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. <i>The Hematology Journal</i> , 2001, 2, 272-278.	1.4	50
383	High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. <i>Leukemia Research</i> , 2009, 33, 1706-1709.	0.8	49
384	Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?. <i>Blood Reviews</i> , 2011, 25, 181-191.	5.7	49
385	Blast Crisis of Chronic Granulocytic Leukemia with Mast Cell and Basophilic Precursors. <i>American Journal of Clinical Pathology</i> , 1985, 83, 254-259.	0.7	48
386	Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. <i>Transplant Infectious Disease</i> , 2001, 3, 44-46.	1.7	48
387	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.	3.7	48
388	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	5.7	48
389	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 737-748.	2.4	48
390	Adolescent body mass index and erythrocyte sedimentation rate in relation to colorectal cancer risk. <i>Gut</i> , 2016, 65, 1289-1295.	12.1	48
391	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	2.5	48
392	Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 241-245.	2.1	47
393	Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. <i>American Journal of Hematology</i> , 2009, 84, 149-152.	4.1	47
394	<i>p53</i> deletion may drive the clinical evolution and treatment response in multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 359-361.	2.2	47
395	Long FLT3 internal tandem duplications and reduced PML-RAR α expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. <i>Haematologica</i> , 2010, 95, 745-751.	3.5	47
396	Effects of MSC Coadministration and Route of Delivery on Cord Blood Hematopoietic Stem Cell Engraftment. <i>Cell Transplantation</i> , 2013, 22, 1171-1183.	2.5	47

#	ARTICLE	IF	CITATIONS
397	CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. <i>Haematologica</i> , 2011, 96, 328-332.	3.5	46
398	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	10.7	46
399	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.	4.6	46
400	The effect of vitamin D ₃ metabolites on normal and leukemic bone marrow cells in vitro. <i>International Journal of Cell Cloning</i> , 1984, 2, 227-242.	1.6	45
401	Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. <i>British Journal of Cancer</i> , 1993, 68, 1227-1231.	6.4	45
402	Increased interleukin-12 serum levels in chronic alcoholism. <i>Journal of Hepatology</i> , 1998, 28, 771-777.	3.7	45
403	Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 67-75.	1.3	45
404	Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. <i>International Journal of Cancer</i> , 2004, 112, 884-889.	5.1	45
405	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. <i>Clinical Cancer Research</i> , 2013, 19, 2677-2687.	7.0	45
406	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	2.7	45
407	Increased expression of natural-killer-associated and activation antigens in multiple myeloma. <i>American Journal of Hematology</i> , 1992, 39, 84-89.	4.1	44
408	Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability. <i>PLoS ONE</i> , 2015, 10, e0121581.	2.5	44
409	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 1334-1339.	3.5	44
410	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. <i>Leukemia</i> , 2017, 31, 1446-1449.	7.2	44
411	Roadmap to cure multiple myeloma. <i>Cancer Treatment Reviews</i> , 2021, 100, 102284.	7.7	44
412	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , the, 2022, 9, e143-e161.	4.6	44
413	High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. <i>Haematologica</i> , 2003, 88, 1372-7.	3.5	44
414	Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. <i>Leukemia</i> , 2005, 19, 1088-1091.	7.2	43

#	ARTICLE	IF	CITATIONS
415	Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues. <i>Oncology</i> , 2006, 70, 474-482.	1.9	43
416	Genomic analysis of high-risk smoldering multiple myeloma. <i>Haematologica</i> , 2012, 97, 1439-1443.	3.5	43
417	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	1.4	43
418	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , 2014, 5, 8284-8305.	1.8	43
419	Chronic graft-versus-host disease of the kidney in patients with allogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2013, 91, 129-134.	2.2	42
420	NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2014, 20, 4014-4025.	7.0	42
421	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	3.5	42
422	Is immunotherapy here to stay in multiple myeloma?. <i>Haematologica</i> , 2017, 102, 423-432.	3.5	42
423	The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. <i>Haematologica</i> , 2008, 93, 1797-1805.	3.5	41
424	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e53-e55.	3.5	41
425	Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?. <i>Clinical Cancer Research</i> , 2015, 21, 2001-2008.	7.0	41
426	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. <i>Leukemia</i> , 2020, 34, 589-603.	7.2	41
427	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	1.4	41
428	Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease. <i>British Journal of Haematology</i> , 1995, 91, 941-943.	2.5	40
429	Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor B-ALL. <i>British Journal of Haematology</i> , 1999, 104, 695-705.	2.5	40
430	Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. <i>Bone Marrow Transplantation</i> , 2004, 34, 729-738.	2.4	40
431	Prognostic Factors and Staging in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1115-1140.	2.2	40
432	Bortezomib in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 701-715.	1.7	40

#	ARTICLE	IF	CITATIONS
433	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). <i>Annals of Hematology</i> , 2010, 89, 453-458.	1.8	40
434	How to Manage Neutropenia in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 5-11.	0.4	40
435	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 519-530.	0.4	40
436	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	4.1	40
437	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3151-3161.	1.6	40
438	Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML. <i>British Journal of Haematology</i> , 1995, 89, 338-341.	2.5	39
439	Distribution of Peripheral Blood Lymphoid Subsets in Alcoholic Liver Cirrhosis: Influence of Ethanol Intake. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1564-1568.	2.4	39
440	Alterations in Tumor Necrosis Factor-alpha, Interferon-gamma, and Interleukin-6 Production by Natural Killer Cell-Enriched Peripheral Blood Mononuclear Cells in Chronic Alcoholism: Relationship with Liver Disease and Ethanol Intake. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 1226-1231.	2.4	39
441	Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. , 1998, 34, 264-271.		39
442	Lenalidomide: A new therapy for multiple myeloma. <i>Cancer Treatment Reviews</i> , 2008, 34, 283-291.	7.7	39
443	Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 175, 448-456.	2.5	39
444	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 34.	6.2	39
445	Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. <i>The Hematology Journal</i> , 2002, 3, 121-130.	1.4	39
446	Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. <i>Haematologica</i> , 2006, 91, 621-7.	3.5	39
447	Low frequency of the TEL/AML1 fusion gene in acute lymphoblastic leukaemia in Spain. <i>British Journal of Haematology</i> , 1999, 107, 667-669.	2.5	38
448	Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. <i>Cancer</i> , 2003, 97, 601-609.	4.1	38
449	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. <i>Leukemia</i> , 2003, 17, 1398-1403.	7.2	38
450	Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anemic Patients with Lymphoproliferative Malignancies. <i>Journal of Pain and Symptom Management</i> , 2006, 31, 317-325.	1.2	38

#	ARTICLE	IF	CITATIONS
451	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 44-49.	0.4	38
452	Bone Marrow Mesenchymal Stem Cells for Improving Hematopoietic Function: An In Vitro and In Vivo Model. Part 2: Effect on Bone Marrow Microenvironment. <i>PLoS ONE</i> , 2011, 6, e26241.	2.5	38
453	Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment. <i>Clinical Cancer Research</i> , 2012, 18, 2145-2163.	7.0	38
454	A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. <i>British Journal of Haematology</i> , 2015, 170, 804-813.	2.5	38
455	Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. <i>Leukemia</i> , 2018, 32, 971-978.	7.2	38
456	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2019, 134, 781-781.	1.4	38
457	Immunophenotypical detection of minimal residual disease in acute leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 175-185.	4.4	37
458	The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. <i>Transfusion</i> , 2002, 42, 1159-1172.	1.6	37
459	FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. <i>The Hematology Journal</i> , 2004, 5, 239-246.	1.4	37
460	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	7.2	37
461	The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. <i>British Journal of Haematology</i> , 1999, 106, 400-405.	2.5	36
462	Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 936-941.	2.0	36
463	Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. <i>British Journal of Haematology</i> , 2013, 162, 474-482.	2.5	36
464	Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. <i>Haematologica</i> , 2013, 98, 279-287.	3.5	36
465	Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. <i>World Journal of Stem Cells</i> , 2014, 6, 322.	2.8	36
466	Immunophenotypic analysis of myelodysplastic syndromes. <i>Haematologica</i> , 2003, 88, 402-7.	3.5	36
467	Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution. <i>Annals of Hematology</i> , 1993, 67, 217-222.	1.8	35
468	Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. <i>The Hematology Journal</i> , 2004, 5, 227-233.	1.4	35

#	ARTICLE	IF	CITATIONS
469	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. <i>British Journal of Haematology</i> , 2008, 141, 470-482.	2.5	35
470	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. <i>Blood Reviews</i> , 2009, 23, 87-93.	5.7	35
471	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 775-790.	2.2	35
472	Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. <i>American Journal of Pathology</i> , 2016, 186, 2171-2182.	3.8	35
473	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. <i>Genome Research</i> , 2020, 30, 1217-1227.	5.5	35
474	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	7.2	35
475	Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. , 1998, 34, 223-228.		34
476	IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases. <i>British Journal of Haematology</i> , 1998, 103, 163-167.	2.5	34
477	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , 2012, 97, 1110-1114.	3.5	34
478	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	10.9	34
479	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. <i>Blood</i> , 2016, 127, 3035-3039.	1.4	34
480	Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1991, 79, 408-414.	2.5	33
481	Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. <i>Blood</i> , 2003, 102, 2699-2700.	1.4	33
482	CD34+ Cells from Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Normal Bone Marrow Display Different Apoptosis and Drug Resistance-Associated Phenotypes. <i>Clinical Cancer Research</i> , 2004, 10, 7599-7606.	7.0	33
483	Prognostic features of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 569-583.	1.7	33
484	Deficient Spindle Assembly Checkpoint in Multiple Myeloma. <i>PLoS ONE</i> , 2011, 6, e27583.	2.5	33
485	Living at Higher Altitude and Incidence of Overweight/Obesity: Prospective Analysis of the SUN Cohort. <i>PLoS ONE</i> , 2016, 11, e0164483.	2.5	33
486	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33

#	ARTICLE	IF	CITATIONS
487	Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 23-28.	1.0	32
488	Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q. <i>British Journal of Haematology</i> , 2006, 133, 642-645.	2.5	32
489	The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib. <i>Oncologist</i> , 2007, 12, 281-290.	3.7	32
490	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	4.5	32
491	DNA Cell Content Studies in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1996, 23, 33-41.	1.3	31
492	Treatment of Multiple Myeloma in Elderly People: Long-term Results in 178 Patients. <i>Age and Ageing</i> , 1996, 25, 357-361.	1.6	31
493	Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 901-905.	2.4	31
494	Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Mieloma "sea phase II trial. <i>British Journal of Haematology</i> , 2003, 120, 296-303.	2.5	31
495	Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. <i>Haematologica</i> , 2008, 93, 851-859.	3.5	31
496	Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 117-124.	2.5	31
497	Molecular Characterization of Immunoglobulin Gene Rearrangements in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2012, 181, 1879-1888.	3.8	31
498	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	7.2	31
499	Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. <i>Haematologica</i> , 2005, 90, 54-9.	3.5	31
500	Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. <i>Blood Advances</i> , 2022, 6, 1309-1318.	5.2	31
501	A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma. <i>Blut</i> , 1990, 60, 319-322.	1.2	30
502	p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. <i>The Hematology Journal</i> , 2001, 2, 146-149.	1.4	30
503	Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 212-215.	2.5	29
504	Limbus Damage in Ocular Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 270-273.	2.0	29

#	ARTICLE	IF	CITATIONS
505	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. <i>Haematologica</i> , 2011, 96, 468-471.	3.5	29
506	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 40, 1-9.	0.8	29
507	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	1.4	29
508	B-cell chronic lymphocytic leukaemia: Prognostic value of the immunophenotype and the clinico-haematological features. <i>American Journal of Hematology</i> , 1989, 31, 26-31.	4.1	28
509	Prognostic value of Sâ€phase cells in AML patients. <i>British Journal of Haematology</i> , 1995, 89, 342-348.	2.5	28
510	Abnormalities of Peripheral Blood T Lymphocytes and Natural Killer Cells in Alcoholic Hepatitis Persist after a 3-Month Withdrawal Period. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 672-676.	2.4	28
511	Neurological Complications after Autologous Stem Cell Transplantation. <i>European Neurology</i> , 1999, 41, 48-50.	1.4	28
512	Immunophenotyping of Plasma Cells in Multiple Myeloma. , 2005, 113, 5-24.		28
513	The role of immature platelet fraction in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 103, 247-249.	3.4	28
514	Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 768-773.	1.2	28
515	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , 2016, 22, 4206-4214.	7.0	28
516	Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. <i>Leukemia</i> , 2021, 35, 1438-1450.	7.2	28
517	Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1866-1866.	1.4	28
518	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , 2016, 128, 246-246.	1.4	28
519	Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. <i>Haematologica</i> , 2002, 87, 822-7.	3.5	28
520	Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkinâ€™s lymphomas. <i>Leukemia</i> , 1997, 11, 1915-1920.	7.2	27
521	Sequential analysis of CD34+ and CD34â€™ cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. <i>Leukemia</i> , 2001, 15, 430-439.	7.2	27
522	Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML). <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 105-118.	1.7	27

#	ARTICLE	IF	CITATIONS
523	Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. <i>Leukemia</i> , 2003, 17, 1051-1057.	7.2	27
524	Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. <i>British Journal of Haematology</i> , 2013, 163, 581-589.	2.5	27
525	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015, 100, 1294-1300.	3.5	27
526	Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. <i>Annals of Hematology</i> , 2016, 95, 2033-2041.	1.8	27
527	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	1.3	27
528	Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e26-e27.	0.4	27
529	An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 176-176.	1.4	27
530	A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 509-509.	1.4	27
531	Distribution of the CD45R antigen in the maturation of lymphoid and myeloid series: the CD45R negative phenotype is a constant finding in T CD4 positive lymphoproliferative disorders. <i>British Journal of Haematology</i> , 1988, 69, 173-179.	2.5	26
532	Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society) <i>Tj ETQq0 07rgBT /O2erlock 10</i>	0.7	26
533	Influence of the different CD34+ and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors. <i>British Journal of Haematology</i> , 2002, 119, 135-143.	2.5	26
534	Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 437-447.	2.0	26
535	Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. <i>Cytotherapy</i> , 2007, 9, 14-22.	0.7	26
536	Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. <i>Leukemia</i> , 2007, 21, 797-804.	7.2	26
537	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. <i>Oncologist</i> , 2011, 16, 388-403.	3.7	26
538	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	7.2	26
539	Laparoscopic Diagnosis of Tuberculous Ascites. <i>Endoscopy</i> , 1982, 14, 178-179.	1.8	25
540	Flow cytometry in the diagnosis of cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 145-152.	1.2	25

#	ARTICLE	IF	CITATIONS
541	Reduced-Intensity Conditioning Allogeneic Transplantation from Unrelated Donors: Evaluation of Mycophenolate Mofetil Plus Cyclosporin A as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 664-671.	2.0	25
542	Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. <i>International Journal of Cancer</i> , 2009, 124, 367-375.	5.1	25
543	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	2.4	25
544	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. <i>Journal of Hematology and Oncology</i> , 2017, 10, 127.	17.0	25
545	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017, 117, 185-191.	7.1	25
546	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , 2021, 106, 1725-1732.	3.5	25
547	T-cell subpopulations in patients with monoclonal gammopathies: Essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia. <i>American Journal of Hematology</i> , 1985, 20, 267-273.	4.1	24
548	Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. <i>British Journal of Haematology</i> , 1995, 89, 104-109.	2.5	24
549	Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. <i>Cytometry</i> , 1995, 22, 217-222.	1.8	24
550	Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. <i>Bone Marrow Transplantation</i> , 2000, 25, 217-218.	2.4	24
551	Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. <i>British Journal of Haematology</i> , 2002, 117, 890-892.	2.5	24
552	CD34?+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 177-183.	1.3	24
553	Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. <i>Haematologica</i> , 2007, 92, 1295-1296.	3.5	24
554	Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 618-633.	2.2	24
555	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective caseâ€‘matched study. <i>American Journal of Hematology</i> , 2014, 89, 355-362.	4.1	24
556	Introduction to a series of reviews on multiple myeloma. <i>Blood</i> , 2015, 125, 3039-3040.	1.4	24
557	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 35-48.	3.1	24
558	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017, 10, 229-237.	2.2	24

#	ARTICLE	IF	CITATIONS
559	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018, 245, 61-73.	4.5	24
560	Measurable residual disease in multiple myeloma: ready for clinical practice?. <i>Journal of Hematology and Oncology</i> , 2020, 13, 82.	17.0	24
561	18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. <i>Cancers</i> , 2020, 12, 1042.	3.7	24
562	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	1.4	24
563	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 273-284.	5.0	24
564	Detection of the Mbcrl/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: Comparison with conventional cytogenetics and implications for minimal residual disease detection. <i>Human Pathology</i> , 1997, 28, 154-159.	2.0	23
565	Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 1229-1230.	2.4	23
566	Renin Expression in Hematological Malignancies and its Role in the Regulation of Hematopoiesis. <i>Leukemia and Lymphoma</i> , 2002, 43, 2377-2381.	1.3	23
567	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 122, 1448-1454.	1.4	23
568	Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2014, 9, e92378.	2.5	23
569	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014, 99, 155-162.	3.5	23
570	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	1.4	23
571	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414.	4.6	23
572	Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. <i>British Journal of Haematology</i> , 1992, 82, 671-675.	2.5	22
573	Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials. <i>American Journal of Pathology</i> , 2012, 181, 1870-1878.	3.8	22
574	Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, e63-e67.	3.5	22
575	Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 353-366.	1.9	22
576	A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 99-106.	2.8	22

#	ARTICLE	IF	CITATIONS
577	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematological Oncology, 2017, 35, 746-751.	1.7	22
578	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 785-798.	0.4	22
579	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	3.5	22
580	Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalanâ€Prednisone Versus Melphalanâ€Prednisone in Newly Diagnosed Multiple Myeloma. Blood, 2008, 112, 650-650.	1.4	22
581	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. Blood, 2015, 126, 28-28.	1.4	22
582	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux. Blood, 2016, 128, 1151-1151.	1.4	22
583	Development of acute leukaemia after idiopathic myelofibrosis.. Journal of Clinical Pathology, 1992, 45, 427-430.	2.0	21
584	Clonality analysis for antigen receptor genes: Preliminary results from the biomed-2 concerted action PL 96-3936. Human Pathology, 2003, 34, 359-361.	2.0	21
585	Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2004, 33, 183-187.	2.4	21
586	Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired. Oncologist, 2008, 13, 82-92.	3.7	21
587	Effect of vitamin D treatment in chronic GVHD. Bone Marrow Transplantation, 2011, 46, 1395-1397.	2.4	21
588	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 207-217.	7.0	21
589	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus lowâ€dose dexamethasone: A pooled analysis. European Journal of Haematology, 2017, 99, 199-206.	2.2	21
590	CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. Journal of Clinical Medicine, 2020, 9, 3577.	2.4	21
591	Preneoplastic somatic mutations including <i>MYD88</i> ^{L265P} in lymphoplasmacytic lymphoma. Science Advances, 2022, 8, eabl4644.	10.3	21
592	The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma. Haematologica, 2004, 89, 1213-8.	3.5	21
593	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. Leukemia, 2001, 15, 121-127.	7.2	20
594	Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. Transfusion, 2012, 52, 1086-1091.	1.6	20

#	ARTICLE	IF	CITATIONS
595	Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. <i>Haematologica</i> , 2015, 100, 1207-1213.	3.5	20
596	Utility of flow cytometry studies in the management of patients with multiple myeloma. <i>Current Opinion in Oncology</i> , 2016, 28, 511-517.	2.4	20
597	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	7.2	20
598	First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2308-2317.	7.0	20
599	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. <i>Blood</i> , 2018, 132, 156-156.	1.4	20
600	Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO). <i>Blood</i> , 2016, 128, 1149-1149.	1.4	20
601	Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. <i>Haematologica</i> , 2005, 90, 906-13.	3.5	20
602	A randomized study comparing the effect of GM-CSF and G-CSF on immune reconstitution after autologous bone marrow transplantation. <i>British Journal of Haematology</i> , 1996, 94, 140-147.	2.5	19
603	Two new 3?PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. , 2000, 27, 35-43.		19
604	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. <i>Haematologica</i> , 2012, 97, 616-621.	3.5	19
605	Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMiDs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1075-1087.	4.1	19
606	Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. <i>Haematologica</i> , 2015, 100, 1096-102.	3.5	19
607	Multiple Myeloma Minimal Residual Disease. <i>Cancer Treatment and Research</i> , 2016, 169, 103-122.	0.5	19
608	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 872-878.	3.5	19
609	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	5.2	19
610	A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib. <i>Blood</i> , 2010, 116, 307-307.	1.4	19
611	Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. <i>Blood</i> , 2017, 130, 838-838.	1.4	19
612	Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial. <i>Blood</i> , 2021, 138, 466-466.	1.4	19

#	ARTICLE	IF	CITATIONS
613	CYTOKINE THERAPY IN MULTIPLE MYELOMA*. British Journal of Haematology, 1996, 94, 425-432.	2.5	18
614	Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. British Journal of Haematology, 2000, 109, 658-660.	2.5	18
615	The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia, 2000, 14, 1493-1499.	7.2	18
616	Functional class switch recombination may occur "in vivo" in Waldenström macroglobulinaemia. British Journal of Haematology, 2007, 136, 114-116.	2.5	18
617	Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica, 2008, 93, 1343-1350.	3.5	18
618	The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Annals of Hematology, 2013, 92, 97-100.	1.8	18
619	Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control. British Journal of Haematology, 2016, 173, 754-768.	2.5	18
620	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PLoS ONE, 2018, 13, e0203392.	2.5	18
621	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1518-1526.	3.5	18
622	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.	3.5	18
623	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Advances, 2021, 5, 760-770.	5.2	18
624	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone. Blood, 2019, 134, 859-859.	1.4	18
625	Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial. Blood, 2017, 130, 905-905.	1.4	18
626	Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: biclonality versus intraclonal evolution of a single tumor cell clone. Haematologica, 2006, 91, 331-9.	3.5	18
627	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Advances, 2022, 6, 3234-3239.	5.2	18
628	The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia. Blut, 1986, 52, 357-363.	1.2	17
629	Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplantation, 1999, 23, 997-1002.	2.4	17
630	Factors that influence long-term hematopoietic function following autologous stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 289-293.	2.4	17

#	ARTICLE	IF	CITATIONS
631	Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. <i>Transfusion</i> , 2001, 41, 1212-1216.	1.6	17
632	Bone remodeling markers are useful in the management of monoclonal gammopathies. <i>The Hematology Journal</i> , 2004, 5, 480-488.	1.4	17
633	Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain. <i>Leukemia Research</i> , 2006, 30, 943-948.	0.8	17
634	Both CD133 ⁺ Cells and Monocytes Provide Significant Improvement for Hindlimb Ischemia, Although They do not Transdifferentiate Into Endothelial Cells. <i>Cell Transplantation</i> , 2010, 19, 103-112.	2.5	17
635	Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 168-171.	0.4	17
636	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. <i>Haematologica</i> , 2012, 97, 1608-1611.	3.5	17
637	New Approaches to Smoldering Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 270-276.	2.3	17
638	Multiple myeloma: a model for scientific and clinical progress. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 1-7.	2.5	17
639	The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. <i>Leukemia</i> , 2015, 29, 1435-1437.	7.2	17
640	Origin of Waldenström's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 136-147.	1.7	17
641	Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment. <i>Haematologica</i> , 2020, 105, e470-473.	3.5	17
642	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3245-3245.	1.4	17
643	Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor. <i>Blood</i> , 2018, 132, 3272-3272.	1.4	17
644	A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2008, 112, 2781-2781.	1.4	17
645	Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. <i>Bone Marrow Transplantation</i> , 2002, 30, 63-68.	2.4	16
646	Should prophylactic granulocyte colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?. <i>British Journal of Haematology</i> , 2008, 140, 324-326.	2.5	16
647	How to treat a newly diagnosed young patient with multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 555-565.	2.5	16
648	Performance evaluation of triple-branch GSC diversity receivers over generalized-K fading channels. <i>IEEE Communications Letters</i> , 2009, 13, 829-831.	4.1	16

#	ARTICLE	IF	CITATIONS
649	First report of the nipa palm hispid <i>Octodonta nipae</i> on queen palms in Cyprus. <i>Phytoparasitica</i> , 2011, 39, 51-54.	1.2	16
650	Uptake and delivery of antigens by mesenchymal stromal cells. <i>Cytotherapy</i> , 2013, 15, 673-678.	0.7	16
651	The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. <i>Advances in Therapy</i> , 2016, 33, 1896-1920.	2.9	16
652	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	2.5	16
653	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 14.	6.2	16
654	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016, 128, 3307-3307.	1.4	16
655	Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial. <i>Blood</i> , 2017, 130, 743-743.	1.4	16
656	Ligand-dependent transformation by the receptor for human granulocyte/macrophage colony-stimulating factor and tyrosine phosphorylation of the receptor beta subunit.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3963-3967.	7.1	15
657	Myelodysplastic syndromes. <i>Critical Reviews in Oncology/Hematology</i> , 1996, 23, 57-93.	4.4	15
658	Heterogeneity of structural abnormalities in the 7q31.3â¼q34 region in myeloid malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2004, 150, 136-143.	1.0	15
659	Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. <i>Bone Marrow Transplantation</i> , 2006, 37, 337-338.	2.4	15
660	The DAC system and associations with multiple myeloma. <i>Investigational New Drugs</i> , 2010, 28, 28-35.	2.6	15
661	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 1187-1195.	3.5	15
662	The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. <i>Haematologica</i> , 2012, 97, 1329-1337.	3.5	15
663	Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative <scp>PCR</scp> in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012, 89, 328-335.	2.2	15
664	Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. <i>Annals of Oncology</i> , 2015, 26, 2247-2256.	1.2	15
665	Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. <i>Hematological Oncology</i> , 2018, 36, 463-470.	1.7	15
666	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 6023-6033.	5.2	15

#	ARTICLE	IF	CITATIONS
667	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	1.4	15
668	Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 2105-2105.	1.4	15
669	Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8512-8512.	1.6	15
670	Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD). <i>European Journal of Cancer</i> , 1993, 29, 57-60.	2.8	14
671	Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 665-672.	2.4	14
672	Relapse/Refractory Myeloma Patient: Potential Treatment Guidelines. <i>Journal of Clinical Oncology</i> , 2009, 27, 5676-5677.	1.6	14
673	Frequency of HLA- α , β and ϵ DRB1 specificities and haplotypic associations in the population of Castilla y Le \acute{o} n (northwest-central Spain). <i>Tissue Antigens</i> , 2011, 78, 249-255.	1.0	14
674	Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: Effect of 5-AZA treatment. <i>Leukemia Research</i> , 2012, 36, 895-899.	0.8	14
675	Human Bone Marrow Stromal Cells Differentiate into Corneal Tissue and Prevent Ocular Graft-Versus-Host Disease in Mice. <i>Cell Transplantation</i> , 2015, 24, 2423-2433.	2.5	14
676	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
677	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.	1.4	14
678	Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 3187-3187.	1.4	14
679	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2598-2609.	7.0	14
680	Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. <i>Blood Cancer Journal</i> , 2021, 11, 202.	6.2	14
681	TdT activity in acute myeloid leukemias defined by monoclonal antibodies. <i>American Journal of Hematology</i> , 1986, 23, 9-17.	4.1	13
682	Clinical and immunological findings in large B-cell chronic lymphocytic leukemia. <i>Clinical Immunology and Immunopathology</i> , 1988, 46, 177-185.	2.0	13
683	The Relationship Between Hyperthyroidism and the Distribution of Peripheral Blood T, NK and B-Lymphocytes in Multinodular Goiter. <i>Hormone and Metabolic Research</i> , 1994, 26, 104-108.	1.5	13
684	Light scatter characteristics of blast cells in acute myeloid leukaemia: association with morphology and immunophenotype.. <i>Journal of Clinical Pathology</i> , 1995, 48, 456-462.	2.0	13

#	ARTICLE	IF	CITATIONS
685	Debate Round-Table: Comments concerning chimerism studies. <i>Leukemia</i> , 2001, 15, 1986-1988.	7.2	13
686	Analysis of Methylation Pattern in Multiple Myeloma. <i>Acta Haematologica</i> , 2005, 114, 23-26.	1.4	13
687	Long-term Immune Recovery of Patients Undergoing Allogeneic Stem Cell Transplantation: A Comparison with Their Respective Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 354-361.	2.0	13
688	Relevance of renin expression by real-time PCR in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 409-416.	1.3	13
689	Molecular biology of myeloma. <i>Clinical and Translational Oncology</i> , 2007, 9, 618-624.	2.4	13
690	Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1331-1336.	2.0	13
691	Characterization of haematological parameters with bortezomib+melphalan+prednisone versus melphalan+prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221.	2.5	13
692	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , 2011, 96, 687-695.	3.5	13
693	Multiple myeloma: treatment evolution. <i>Hematology</i> , 2012, 17, s3-s6.	1.5	13
694	Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. <i>Leukemia</i> , 2014, 28, 1747-1750.	7.2	13
695	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	3.5	13
696	Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1703-1712.	2.0	13
697	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111.	6.2	13
698	Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. <i>British Journal of Haematology</i> , 2021, 194, 132-139.	2.5	13
699	VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2018, 132, 126-126.	1.4	13
700	An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 1850-1850.	1.4	13
701	Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).. <i>Blood</i> , 2007, 110, 2712-2712.	1.4	13
702	Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan+Prednisone Versus Melphalan+Prednisone. <i>Blood</i> , 2008, 112, 2778-2778.	1.4	13

#	ARTICLE	IF	CITATIONS
703	New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM). Blood, 2016, 128, 2096-2096.	1.4	13
704	Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 161-161.	1.4	13
705	Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study. Blood, 2021, 138, 1647-1647.	1.4	13
706	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	13
707	Immunophenotypic characterisation of acute leukaemia after polycythemia vera.. Journal of Clinical Pathology, 1993, 46, 668-671.	2.0	12
708	Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics. Annals of Hematology, 1997, 75, 81-86.	1.8	12
709	Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. British Journal of Haematology, 2002, 119, 883-884.	2.5	12
710	Consolidation therapy in myeloma: a consolidated approach?. Blood, 2012, 120, 2-3.	1.4	12
711	Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. Annals of Hematology, 2012, 91, 1887-1895.	1.8	12
712	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leukemia Research Reports, 2015, 4, 64-69.	0.4	12
713	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. Haematologica, 2018, 103, 880-889.	3.5	12
714	Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. Journal of Clinical Pharmacology, 2021, 61, 614-627.	2.0	12
715	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. American Journal of Hematology, 2021, 96, 896-900.	4.1	12
716	Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex). Blood, 2020, 136, 8-9.	1.4	12
717	Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study. Blood, 2015, 126, 721-721.	1.4	12
718	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. Blood, 2021, 138, 1829-1829.	1.4	12
719	MRD in multiple myeloma: does CR really matter?. Blood, 2022, 140, 2423-2428.	1.4	12
720	Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use. Transfusion Medicine, 2012, 22, 122-127.	1.1	11

#	ARTICLE	IF	CITATIONS
721	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. <i>Investigational New Drugs</i> , 2013, 31, 200-205.	2.6	11
722	Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells. <i>Cancer Cell</i> , 2015, 28, 281-283.	16.8	11
723	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	1.4	11
724	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. <i>Blood Cancer Journal</i> , 2019, 9, 36.	6.2	11
725	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	2.2	11
726	Daratumumab With Cetrelimab, an Anti-“PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 46-54.e4.	0.4	11
727	Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. <i>Leukemia</i> , 2021, 35, 3012-3016.	7.2	11
728	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.	1.4	11
729	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	3.7	11
730	Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8002-8002.	1.6	11
731	Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse. <i>Oncotarget</i> , 2016, 7, 80664-80679.	1.8	11
732	Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. <i>Haematologica</i> , 2003, 88, 1013-21.	3.5	11
733	Alpha interferon in the management of essential thrombocythaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, S72-S74.	0.7	10
734	Rhabdomyolysis associated with septicemia after autologous bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 95-95.	2.4	10
735	Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 1997, 74, 79-82.	1.8	10
736	Pathologic rupture of the spleen during induction with ATRA in a patient with acute promyelocytic leukemia. <i>Medical Oncology</i> , 2000, 17, 337-339.	2.5	10
737	Immunologic monitoring in adults with acute lymphoblastic leukemia. <i>Current Oncology Reports</i> , 2003, 5, 413-418.	4.0	10
738	Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. <i>Bone Marrow Transplantation</i> , 2004, 34, 675-682.	2.4	10

#	ARTICLE	IF	CITATIONS
739	Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability. <i>Experimental Hematology</i> , 2005, 33, 935-943.	0.4	10
740	Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. <i>Hematological Oncology</i> , 2006, 24, 205-211.	1.7	10
741	Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e289-e291.	3.5	10
742	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. <i>Leukemia</i> , 2021, 35, 245-249.	7.2	10
743	Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2018, 132, 1996-1996.	1.4	10
744	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 408-408.	1.4	10
745	Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma. <i>Blood</i> , 2015, 126, 117-117.	1.4	10
746	High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 482-482.	1.4	10
747	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999, 94, 1192-1200.	1.4	10
748	New Tools for Diagnosis and Monitoring of Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e313-e318.	3.8	10
749	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	2.5	10
750	Cytogenetic Heterogeneity in Clonal Plasma Cell Disorders: A Study in Highly Purified Aberrant Plasma Cells. <i>Blood</i> , 2012, 120, 3945-3945.	1.4	10
751	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. <i>Advances in Therapy</i> , 2022, 39, 1976-1992.	2.9	10
752	A Monoclonal Antibody GR2110 Reactive With a P24 Antigen Present in a Subgroup of Acute Lymphoid Leukemias. <i>Hybridoma</i> , 1985, 4, 369-378.	0.6	9
753	An abnormal CD34+myeloid/CD34+lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. , 1999, 38, 70-75.		9
754	Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 68-72.	1.0	9
755	Molecular Characterization of Complete and Incomplete Immunoglobulin Heavy Chain Gene Rearrangements in Hairy Cell Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 573-579.	1.4	9
756	The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2010, 84, 266-270.	2.2	9

#	ARTICLE	IF	CITATIONS
757	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. Haematologica, 2017, 102, 168-175.	3.5	9
758	The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia and Lymphoma, 2020, 61, 680-690.	1.3	9
759	Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora's Box of Multiple Myeloma. Cancers, 2022, 14, 1430.	3.7	9
760	Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: Phenotypic and genomic differences. American Journal of Hematology, 1993, 43, 256-258.	4.1	8
761	Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients. Hematology and Cell Therapy, 1997, 39, 223-227.	0.7	8
762	Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities. Leukemia Research, 2004, 28, 1181-1187.	0.8	8
763	New Tools for Diagnosis and Monitoring of Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e313-e318.	3.8	8
764	Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?. Haematologica, 2014, 99, 5-6.	3.5	8
765	Initial treatment of transplant-ineligible patients in multiple myeloma. Expert Review of Hematology, 2014, 7, 67-77.	2.2	8
766	Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 2016, 172, 625-628.	2.5	8
767	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia, 2018, 32, 2427-2434.	7.2	8
768	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. British Journal of Haematology, 2021, 192, 522-530.	2.5	8
769	Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer, 2021, 21, 659.	2.6	8
770	Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance. The Hematology Journal, 2003, 4, 67-70.	1.4	8
771	Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO). Blood, 2018, 132, 2006-2006.	1.4	8
772	Incidence, Clinical Features, and Outcome of All-Trans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 1998, 92, 2712-2718.	1.4	8
773	Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study. Blood, 2021, 138, 1677-1677.	1.4	8
774	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 68.	6.2	8

#	ARTICLE	IF	CITATIONS
775	T cells subpopulations in untreated and treated patients with haemophilia A and B. <i>Blut</i> , 1983, 47, 311-313.	1.2	7
776	Myelodysplastic syndrome evolving to a mixed myeloid-lymphoid leukaemia. <i>Hematological Oncology</i> , 1986, 4, 175-176.	1.7	7
777	Heterogeneity of T cell lymphoblastic leukaemias.. <i>Journal of Clinical Pathology</i> , 1991, 44, 628-631.	2.0	7
778	Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34 ⁺ bone marrow cell compartments from patients with myelodysplastic syndromes. <i>Leukemia</i> , 2004, 18, 1311-1313.	7.2	7
779	Graft vs. Host Disease and Graft vs. Myeloma Effect after Non-myeloablative Allogeneic Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 1725-1729.	1.3	7
780	Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. <i>Thrombosis Research</i> , 2007, 119, 691-698.	1.7	7
781	Prospective comparative analysis of the angiogenic capacity of monocytes and CD133+ cells in a murine model of hind limb ischemia. <i>Cytotherapy</i> , 2009, 11, 1041-1051.	0.7	7
782	Risk Stratification in the Era of Novel Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 457-464.	2.0	7
783	Treatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 113-119.	2.3	7
784	MyelomaA Genetics International Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 796-800.	1.3	7
785	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 223-234.	2.5	7
786	Induction Therapy for Newly Diagnosed Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 19-28.	4.9	7
787	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 504-516.	4.1	7
788	Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e16-e17.	0.4	7
789	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.	3.7	7
790	Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 480-489.	0.4	7
791	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. <i>Blood Advances</i> , 2021, 5, 1340-1343.	5.2	7
792	Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2018, 132, 2142-2142.	1.4	7

#	ARTICLE	IF	CITATIONS
793	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).. Journal of Clinical Oncology, 2013, 31, 8527-8527.	1.6	7
794	Long-Term Reversibility of Renal Dysfunction Associated to Light Chain Deposition Disease with Bortezomib and Dexamethasone and High Dose Therapy and Autologous Stem Cell Transplantation. Clinics and Practice, 2011, 1, 205-208.	1.4	7
795	Competition Between (Mono)Clonal Plasma Cells and Normal Cells for Potentially Overlapping Bone Marrow Niches Is Associated with a Progressively Altered Cellular Distribution In MGUS Vs. Myeloma. Blood, 2010, 116, 617-617.	1.4	7
796	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. Blood, 2021, 138, 76-76.	1.4	7
797	Assessment of Treatment Response By Iife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial. Blood, 2021, 138, 544-544.	1.4	7
798	CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome. Blood, 2021, 138, 735-735.	1.4	7
799	OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S17-S18.	0.4	7
800	HELPER/SUPPRESSOR T-CELL SUBPOPULATIONS IN BENIGN PARAPROTEINAEMIA. British Journal of Haematology, 1983, 54, 318-320.	2.5	6
801	Dipeptidylaminopeptidase IV (DAP IV) in B- and T-cell leukaemias. International Journal of Laboratory Hematology, 1985, 7, 359-368.	0.2	6
802	In leukemic hematopoiesis CD34 antigen does not have the same significance as it does normal hematopoiesis. Leukemia Research, 1997, 21, 651-656.	0.8	6
803	Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. Bone Marrow Transplantation, 2004, 33, 579-587.	2.4	6
804	Prognostic Impact of Pretransplantation Computed Tomography and Gallium Scans in Patients with Hodgkin Lymphoma with Poor Prognosis Undergoing Hematopoietic Stem Cell Transplantation. Clinical Lymphoma and Myeloma, 2006, 7, 217-225.	1.4	6
805	Smoldering Multiple Myeloma: When to Observe and When to Treat?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e484-e492.	3.8	6
806	V. Smoldering multiple myeloma. Hematological Oncology, 2015, 33, 33-37.	1.7	6
807	Improved understanding of disease biology and treatment. Nature Reviews Clinical Oncology, 2015, 12, 71-72.	27.6	6
808	Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplantation, 2020, 55, 419-430.	2.4	6
809	Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study. British Journal of Haematology, 2021, 194, e48-e51.	2.5	6
810	Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 413-420.	0.4	6

#	ARTICLE	IF	CITATIONS
811	Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes. Blood, 2019, 134, 506-506.	1.4	6
812	Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2020, 136, 10-11.	1.4	6
813	The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.. Blood, 2007, 110, 410-410.	1.4	6
814	A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,. Blood, 2011, 118, 3962-3962.	1.4	6
815	Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study. Blood, 2013, 122, 1968-1968.	1.4	6
816	Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2014, 124, 178-178.	1.4	6
817	Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. Blood, 2014, 124, 3465-3465.	1.4	6
818	The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 5190-5190.	1.4	6
819	Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. Blood, 2021, 138, 1739-1739.	1.4	6
820	Bone marrow necrosis and treatment with interferon.. Journal of Clinical Pathology, 1986, 39, 1045-1045.	2.0	5
821	DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers. Cytometry, 1995, 22, 22-25.	1.8	5
822	In vitro autonomous proliferation in ANLL: Clinical and biological significance. Leukemia Research, 1995, 19, 411-416.	0.8	5
823	Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia.. Journal of Clinical Pathology, 1996, 49, 450-452.	2.0	5
824	Clonal myelodysplastic cells present in apheresis product before transplantation. Leukemia, 1998, 12, 1497-1499.	7.2	5
825	Immunoglobulin lambda chain gene rearrangement in a case of acute nonlymphoblastic leukemia. Leukemia, 1999, 13, 485-487.	7.2	5
826	Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. Clinical Biochemistry, 2000, 33, 415-418.	1.9	5
827	Myeloma: Update on supportive care strategies. Current Treatment Options in Oncology, 2003, 4, 247-258.	3.0	5
828	Cell Cycle Analysis of Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 250-252.	2.1	5

#	ARTICLE	IF	CITATIONS
829	Bone marrow mesenchymal stem cells chimerism after allogeneic hematopoietic transplantation. <i>Experimental Hematology</i> , 2006, 34, 7.	0.4	5
830	Frontline Treatment in Elderly Patients With Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 133-142.	3.4	5
831	Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e17-e18.	0.4	5
832	Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 567-569.	2.4	5
833	Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e1-e2.	0.4	5
834	Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e15-e16.	0.4	5
835	Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimism Trial. <i>Blood</i> , 2018, 132, 3278-3278.	1.4	5
836	Bortezomib+“Melphalan+“Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.. <i>Blood</i> , 2008, 112, 1727-1727.	1.4	5
837	Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 3026-3026.	1.4	5
838	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8526-8526.	1.6	5
839	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. <i>Blood Cancer Journal</i> , 2022, 12, 76.	6.2	5
840	Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. <i>Hematological Oncology</i> , 2022, 40, 987-998.	1.7	5
841	Method for the simultaneous labelling of terminal deoxynucleotidyl transferase (TdT) and membrane antigens.. <i>Journal of Clinical Pathology</i> , 1984, 37, 628-632.	2.0	4
842	CYTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF MONOCLONAL GAMMOPATHIES. <i>British Journal of Haematology</i> , 1985, 60, 768-769.	2.5	4
843	PLASMA BLASTIC MULTIPLE MYELOMA: AN IMMUNOLOGICALLY DIFFERENT SUBTYPE. <i>British Journal of Haematology</i> , 1987, 66, 275-281.	2.5	4
844	HYBRID ACUTE LEUKAEMIA. <i>British Journal of Haematology</i> , 1987, 67, 117-118.	2.5	4
845	Bone marrow histopathologic patterns and immunologic phenotype in B-cell chronic lymphocytic leukaemia. <i>Blut</i> , 1988, 57, 19-23.	1.2	4
846	Translocation(15;17)(q22;q21) in a patient with Klinefelter syndrome. <i>Cancer Genetics and Cytogenetics</i> , 1996, 86, 86.	1.0	4

#	ARTICLE	IF	CITATIONS
847	Association between trisomy 8 and the immunophenotype of blast cells from acute leukemias secondary to a myelodysplastic syndrome or chronic myeloproliferative disorders. <i>Annals of Hematology</i> , 1997, 74, 209-214.	1.8	4
848	TCR-gamma gene rearrangement with interstitial deletion within the TRGV2 gene segment is not detected in normal T-lymphocytes. <i>Leukemia</i> , 1998, 12, 251-253.	7.2	4
849	Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma. , 1999, 38, 24-29.		4
850	Effect of High Altitude on Protein Metabolism in Bolivian Children. <i>High Altitude Medicine and Biology</i> , 2002, 3, 377-386.	0.9	4
851	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2004, 5, 285-285.	1.4	4
852	In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression. <i>Transfusion and Apheresis Science</i> , 2007, 37, 145-156.	1.0	4
853	Clinical and Prognostic Value of Discrepancies in Microsatellite DNA Regions Between Recipient and Donor in Human Leukocyte Antigen-Identical Allogeneic Transplantation Setting. <i>Transplantation</i> , 2008, 86, 983-990.	1.0	4
854	Influence of antiplatelet-anticoagulant drugs on the need of blood components transfusion after vesical transurethral resection. <i>Archivio Italiano Di Urologia Andrologia</i> , 2015, 87, 136.	0.8	4
855	Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update. <i>Blood</i> , 2019, 134, 3152-3152.	1.4	4
856	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. <i>Blood</i> , 2019, 134, 694-694.	1.4	4
857	Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.. <i>Blood</i> , 2008, 112, 1741-1741.	1.4	4
858	Sustained Response After Short-Medium-Term Treatment With Eltrombopag In Patients With ITP. <i>Blood</i> , 2013, 122, 2323-2323.	1.4	4
859	Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2013, 122, 403-403.	1.4	4
860	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 2120-2120.	1.4	4
861	Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 3390-3390.	1.4	4
862	Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials. <i>Blood</i> , 2015, 126, 19-19.	1.4	4
863	Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN). <i>Blood</i> , 2015, 126, 4180-4180.	1.4	4
864	Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy. <i>Blood</i> , 2013, 122, 3723-3723.	1.4	4

#	ARTICLE	IF	CITATIONS
865	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017, 130, 902-902.	1.4	4
866	Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma. <i>Haematologica</i> , 2005, 90, 78-85.	3.5	4
867	Hypertriglyceridemia in Patients with Typhoid Fever. <i>Journal of Infectious Diseases</i> , 1983, 147, 606-606.	4.0	3
868	Changes in surface antigens of HL-60 cells during differentiation in vitro. <i>Blut</i> , 1984, 49, 369-373.	1.2	3
869	Letter to the editor: T-cell subsets and myeloma cell mass. <i>American Journal of Hematology</i> , 1987, 25, 235-236.	4.1	3
870	Skin involvement in non-secretory myeloma. <i>American Journal of Medicine</i> , 1988, 84, 373-374.	1.5	3
871	Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, S48-S49.	0.7	3
872	The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML. <i>Annals of Hematology</i> , 1994, 68, 233-236.	1.8	3
873	Multiparametric cell-cycle analysis of peripheral blood-activated lymphocyte subsets using staining based on the TdT method for incorporated BrdUrd. <i>Cytometry</i> , 1996, 25, 317-323.	1.8	3
874	Detection of monoclonality in bone marrow plasma cells by flow cytometry: limitations for minimal residual disease detection. <i>British Journal of Haematology</i> , 1996, 93, 251-252.	2.5	3
875	A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses. <i>Annals of Hematology</i> , 2003, 82, 750-758.	1.8	3
876	Evolving Treatment Strategies for Anaemia in Cancer: Experience with Epoetin Beta. <i>Oncology</i> , 2004, 67, 17-22.	1.9	3
877	The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. <i>Tissue Antigens</i> , 2008, 71, 548-551.	1.0	3
878	Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma. <i>Medicina Clínica</i> , 2017, 148, 517-523.	0.6	3
879	Waldenström's Macroglobulinemia Immunophenotype. , 2017, , 21-34.		3
880	Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e164-e165.	0.4	3
881	Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis. <i>British Journal of Haematology</i> , 2020, 189, 860-868.	2.5	3
882	Two new 3q2 PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 27, 35-43.	2.8	3

#	ARTICLE	IF	CITATIONS
883	Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. Blood, 2018, 132, 112-112.	1.4	3
884	Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial. Blood, 2018, 132, 1943-1943.	1.4	3
885	Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.. Blood, 2007, 110, 1510-1510.	1.4	3
886	Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). Blood, 2013, 122, 2155-2155.	1.4	3
887	Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study. Blood, 2014, 124, 4742-4742.	1.4	3
888	Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients. Blood, 2015, 126, 2971-2971.	1.4	3
889	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. Blood, 2015, 126, 3031-3031.	1.4	3
890	OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S3-S4.	0.4	3
891	The research mission in myeloma. Leukemia, 2009, 23, 422-423.	7.2	2
892	Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response. Leukemia Research, 2009, 33, 170-173.	0.8	2
893	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. American Journal of Hematology, 2010, 85, 290-293.	4.1	2
894	Prognosis and Staging of Multiple Myeloma. , 2013, , 615-636.		2
895	Lección Magistral Andrés Laguna: el tratamiento del mieloma múltiple. Revista Clínica Española, 2014, 214, 466-469.	0.6	2
896	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs Lenalidomide and Dexamethasone (Rd) in Patients (Pts) With Relapsed Multiple Myeloma (RMM) Based on Age: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e75-e76.	0.4	2
897	KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naïve multiple myeloma (MM). Annals of Oncology, 2016, 27, viii16.	1.2	2
898	CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S330.	0.4	2
899	Diagnosis and Staging of Multiple Myeloma and Related Disorders. Hematologic Malignancies, 2018, , 17-28.	0.2	2
900	Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e47.	0.4	2

#	ARTICLE	IF	CITATIONS
901	Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison. <i>Blood</i> , 2018, 132, 3553-3553.	1.4	2
902	Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial. <i>Blood</i> , 2018, 132, 433-433.	1.4	2
903	Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis. <i>Blood</i> , 2018, 132, 4741-4741.	1.4	2
904	The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD). <i>Blood</i> , 2019, 134, 509-509.	1.4	2
905	Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. <i>Blood</i> , 2013, 122, 2939-2939.	1.4	2
906	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). <i>Blood</i> , 2013, 122, 3198-3198.	1.4	2
907	Dual Antitumoral and Bone Antiresorptive Effect Of The Pan-Pim Kinase Inhibitor, LGH447, In Multiple Myeloma. <i>Blood</i> , 2013, 122, 4435-4435.	1.4	2
908	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 686-686.	1.4	2
909	Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2014, 124, 3457-3457.	1.4	2
910	Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies. <i>Blood</i> , 2014, 124, 3532-3532.	1.4	2
911	Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years. <i>Blood</i> , 2015, 126, 1848-1848.	1.4	2
912	Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 367-367.	1.4	2
913	Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hybridization (FISH). <i>Blood</i> , 2015, 126, 4243-4243.	1.4	2
914	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3283-3283.	1.4	2
915	Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis. <i>Blood</i> , 2016, 128, 3308-3308.	1.4	2
916	Genomic Profiles of Bone Marrow (BM) Clonal Plasma Cells (PCs) Vs Circulating Tumor Cells (CTCs) and Extramedullary (EM) Plasmacytomas in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4442-4442.	1.4	2
917	Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. <i>Blood</i> , 2016, 128, 4503-4503.	1.4	2
918	Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs). <i>Blood</i> , 2016, 128, 801-801.	1.4	2

#	ARTICLE	IF	CITATIONS
919	Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8511-8511.	1.6	2
920	Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenström's Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms.. Blood, 2005, 106, 503-503.	1.4	2
921	ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).. Blood, 2007, 110, 2721-2721.	1.4	2
922	Bortezomib in the Upfront Treatment of Multiple Myeloma. , 2011, , 53-68.		2
923	Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance. Blood, 2014, 124, 25-25.	1.4	2
924	Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma. Blood, 2014, 124, 2001-2001.	1.4	2
925	The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients. Blood, 2015, 126, 4181-4181.	1.4	2
926	P-178: Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S134-S135.	0.4	2
927	Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial. Blood, 2021, 138, 1662-1662.	1.4	2
928	Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies. Blood, 2021, 138, 541-541.	1.4	2
929	Osteolytic lesion as the presenting feature of chronic granulocytic leukaemia. International Journal of Laboratory Hematology, 1985, 7, 105-112.	0.2	1
930	Acute leukemia of hybrid phenotype: T lymphoid and myelomonocytic markers. Clinical Immunology and Immunopathology, 1985, 35, 139-145.	2.0	1
931	Peculiar cytogenetic finding in T-cell lymphoproliferative disorders. Cancer Genetics and Cytogenetics, 1985, 17, 185-186.	1.0	1
932	Chronic prolymphocytoid leukaemia with an unusual immature immunophenotype.. Journal of Clinical Pathology, 1994, 47, 461-463.	2.0	1
933	Application of Self-Quenched JH Consensus Primers for Real-Time Quantitative PCR of IGH Gene to Minimal Residual Disease Evaluation in Multiple Myeloma. Journal of Molecular Diagnostics, 2006, 8, 364-370.	2.8	1
934	Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation. Annals of Nuclear Medicine, 2008, 22, 251-260.	2.2	1
935	Reply to "Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-1114. Haematologica, 2013, 98, e10-e10.	3.5	1
936	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. Clinical Case Reports (discontinued), 2016, 4, 1096-1100.	0.5	1

#	ARTICLE	IF	CITATIONS
937	How deep is the myeloma iceberg?. Blood, 2018, 132, 2424-2425.	1.4	1
938	Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Id in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S253.	0.4	1
939	Role of lncRNAs as prognostic factor and potential therapeutic target in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e354-e355.	0.4	1
940	FlowCT: A semi-automated workflow for deconvolution of immunophenotypic data and objective reporting on large datasets. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e94.	0.4	1
941	PS1395 COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE. HemaSphere, 2019, 3, 640.	2.7	1
942	Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Microenvironment (TIME) of Multiple Myeloma (MM). Blood, 2018, 132, 4436-4436.	1.4	1
943	VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. Blood, 2018, 132, 4446-4446.	1.4	1
944	A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE). Blood, 2019, 134, 2144-2144.	1.4	1
945	MicroRNA Expression Profiling in Multiple Myeloma: Correlation with Genetic Abnormalities. Blood, 2008, 112, 629-629.	1.4	1
946	Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,. Blood, 2011, 118, 3936-3936.	1.4	1
947	Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression. Blood, 2013, 122, 1973-1973.	1.4	1
948	Tumor and Renal Response in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM. Blood, 2014, 124, 4776-4776.	1.4	1
949	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. Blood, 2015, 126, 2962-2962.	1.4	1
950	The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone. Blood, 2015, 126, 5354-5354.	1.4	1
951	What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. Blood, 2015, 126, 725-725.	1.4	1
952	Response to Proteasome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study. Blood, 2016, 128, 3436-3436.	1.4	1
953	Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM). Blood, 2016, 128, 373-373.	1.4	1
954	Long Non-Coding RNAs Annotation and Their Involvement in Multiple Myeloma. Blood, 2016, 128, 4420-4420.	1.4	1

#	ARTICLE	IF	CITATIONS
955	The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators. Blood, 2016, 128, 5688-5688.	1.4	1
956	Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.. Journal of Clinical Oncology, 2013, 31, 8583-8583.	1.6	1
957	Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. Blood, 2007, 110, 2740-2740.	1.4	1
958	Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.. Blood, 2007, 110, 729-729.	1.4	1
959	The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2008, 112, 5192-5192.	1.4	1
960	A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).. Blood, 2009, 114, 4140-4140.	1.4	1
961	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. Blood, 2010, 116, 1963-1963.	1.4	1
962	Fluorescence In Situ Hybridization (FISH) Analysis In 160 Patients with IgM Monoclonal Gammopathies. Blood, 2010, 116, 1916-1916.	1.4	1
963	Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar Applicability and Prognosis Impact to Immunophenotypic Response. (A GEM/PETHEMA study),. Blood, 2011, 118, 3951-3951.	1.4	1
964	Myelodysplasia-Associated Immunophenotypic Abnormalities of Bone Marrow (BM) Cells in Multiple Myeloma (MM): Are They Present At Diagnosis or Can Be Induced by Lenalidomide?. Blood, 2011, 118, 5066-5066.	1.4	1
965	Phase II Optimization, Open-Label Clinical Trial of Zalzypis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients. Blood, 2012, 120, 4041-4041.	1.4	1
966	Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM). Blood, 2013, 122, 3188-3188.	1.4	1
967	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 3448-3448.	1.4	1
968	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. Blood, 2016, 128, 375-375.	1.4	1
969	Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO). Blood, 2018, 132, 1995-1995.	1.4	1
970	Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). Blood, 2019, 134, 3064-3064.	1.4	1
971	Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform. Blood, 2019, 134, 1773-1773.	1.4	1
972	Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimism Trial By Patient Age and Prior Stem Cell Transplant. Blood, 2019, 134, 3120-3120.	1.4	1

#	ARTICLE	IF	CITATIONS
973	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. Blood, 2019, 134, 5549-5549.	1.4	1
974	Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia. Blood, 2019, 134, 3762-3762.	1.4	1
975	Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 1852-1852.	1.4	1
976	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received 3 Prior Lines of Therapy. Blood, 2021, 138, 3057-3057.	1.4	1
977	Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. Blood, 2021, 138, 2719-2719.	1.4	1
978	Landscape and clinical significance of long noncoding <scp>RNAs</scp> involved in multiple myeloma expressed fusion transcripts. American Journal of Hematology, 2022, 97, .	4.1	1
979	Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma. Blood, 2020, 136, 13-14.	1.4	1
980	Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma. , 2022, , 173-176.		1
981	Prognostic value of serum paraprotein response kinetics in patients with newly diagnosed multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.4	1
982	Aortoduodenal fistula: Gastrointestinal bleeding and polymicrobial sepsis. Digestive Diseases and Sciences, 1982, 27, 1142-1143.	2.3	0
983	Biphenotypic leukemia in treated Hodgkin's disease.. Journal of Clinical Pathology, 1984, 37, 1314-1315.	2.0	0
984	LEPTOSPIRAS VERSUS LIBERTY. Lancet, The, 1986, 328, 295.	13.7	0
985	Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases. European Journal of Cancer & Clinical Oncology, 1987, 23, 1417-1418.	0.7	0
986	Validation of survival-predictive models in myelodysplastic syndromes. American Journal of Hematology, 1989, 30, 44-44.	4.1	0
987	Increased expression of CD56 and HLA/DR antigens in CD2+ cells from multiple myeloma patients. American Journal of Hematology, 1994, 46, 158-159.	4.1	0
988	Reply to Nowak et al. British Journal of Haematology, 2000, 110, 752-753.	2.5	0
989	Reply to Yanamandra et al. British Journal of Haematology, 2003, 120, 1096-1096.	2.5	0
990	Myeloma. Oncology Times, 2006, 28, 20-21.	0.1	0

#	ARTICLE	IF	CITATIONS
991	The Activity of Spanish and Italian Myeloma Groups. Clinical Lymphoma and Myeloma, 2009, 9, S36-S39.	1.4	0
992	Introduction and overview. Blood Reviews, 2010, 24, S1-S3.	5.7	0
993	Concluding remarks and future directions. Blood Reviews, 2010, 24, S33-S34.	5.7	0
994	Reply to A. Gratwohl. Journal of Clinical Oncology, 2011, 29, e484-e484.	1.6	0
995	San-Miguel JF. Consolidation therapy in myeloma: a consolidated approach? Blood. 2012;120(1):2â€“3.. Blood, 2012, 120, 1963-1963.	1.4	0
996	Application of D-Case to the Data-Upload Flow Diagram Scenario of the Distributed E-Learning System Called KISSEL. , 2012, , .		0
997	Asymptomatic (smoldering) myeloma: treatment strategy. International Journal of Hematologic Oncology, 2013, 2, 445-453.	1.6	0
998	Can CRd be a standard for refractory myeloma?. Blood, 2013, 122, 3092-3093.	1.4	0
999	Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma. Value in Health, 2014, 17, A546.	0.3	0
1000	San-Miguel J, BladÃ© J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (antiâ€“IL-6) in multiple myeloma. Blood. 2014;123(26):4136-4142.. Blood, 2014, 124, 1201-1201.	1.4	0
1001	Authorsâ€™ Response. American Journal of Hematology, 2015, 90, 146-146.	4.1	0
1002	Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. Medicina Clínica (English Edition), 2017, 148, 517-523.	0.2	0
1003	Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e4-e5.	0.4	0
1004	Autologous hematopoietic cell transplants for plasma cell myeloma: One, two, or none?. , 0, , 445-457.		0
1005	Risk Stratification in Newly Diagnosed Smoldering Multiple Myeloma. , 2018, , 1-13.		0
1006	Smoldering Multiple Myeloma. , 2018, , 531-538.		0
1007	Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e32-e33.	0.4	0
1008	MM-339: Effect of Lenalidomide (R) Â± Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S306-S307.	0.4	0

#	ARTICLE	IF	CITATIONS
1009	Monocyte counts: an early index of haemopoietic reconstitution after peripheral blood stem cell transplantation. British Journal of Haematology, 2000, 111, 987-989.	2.5	0
1010	Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acute and Chronic Graft Versus Host Disease after Allogeneic Transplantation.. Blood, 2004, 104, 5157-5157.	1.4	0
1011	Comparisson of Molecular Mechanisms Altered by Treatment with Different Drugs (Doxorubicin,) Tj ETQq1 1 0.784314 rgBT /Overlock Oligonucleotide Microarrays.. Blood, 2004, 104, 2457-2457.	1.4	0
1012	Comparison between Progenitor Cells from Mobilized Peripheral Blood (PB) in Healthy Donors and Non-Hodgkinâ€™s Lymphoma (NHL) Patients.. Blood, 2004, 104, 5002-5002.	1.4	0
1013	NF-ÎB Blockade Induces Apoptosis and Decreases Costimulatory Molecules and IL-12 Secretion of Dendritic Cells, Altering DC Maturation: Role in Induction of Tolerance after Transplantation.. Blood, 2005, 106, 2465-2465.	1.4	0
1014	Endothelial Progenitor Cells (EPC) with Colony Forming Capacity Are Derived from the Monocytic-Macrophage Lineage.. Blood, 2005, 106, 4228-4228.	1.4	0
1015	Bortezomib Induces Selective Depletion of Activated T Lymphocytes and Modifies the Cytokineâ€™s Production Pattern.. Blood, 2005, 106, 615-615.	1.4	0
1016	Influence of GST Gene Polimorphisms in the Develovement of Liver Sinusoidal Obstructive Syndrome in Patients with Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 3084-3084.	1.4	0
1017	Prognostic Factors and Classification in Multiple Myeloma. Translational Medicine Series, 2007, , 115-140.	0.0	0
1018	Translocation t(4;14) Is Not an Adverse Prognostic Factor in Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation.. Blood, 2007, 110, 4743-4743.	1.4	0
1019	The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3014-3014.	1.4	0
1020	The Novel Combination of Sirolimus and Bortezomib Prevents Graft-Versus-Host Disease but Mantains the Graft-Versus-Leukemia Effect After Allogeneic Transplantation.. Blood, 2010, 116, 3738-3738.	1.4	0
1021	Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone. Blood, 2010, 116, 1906-1906.	1.4	0
1022	Effect of Demethylating Agents (5-Azacytidine/5-AzaC) On the Immune Response. Blood, 2010, 116, 2771-2771.	1.4	0
1023	Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis. Blood, 2010, 116, 4051-4051.	1.4	0
1024	Effect of 5-Azacytidine (5-AzaC) In the Expression of PRAME In Acute Myeloid Leukemia (AML). Blood, 2010, 116, 3615-3615.	1.4	0
1025	Immunophenotypic Analysis of Myeloma Precursors: Antigens for Therapeutic Targeting. Blood, 2010, 116, SCI-5-SCI-5.	1.4	0
1026	Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome., Blood, 2011, 118, 3810-3810.	1.4	0

#	ARTICLE	IF	CITATIONS
1027	Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients,. Blood, 2011, 118, 3944-3944.	1.4	0
1028	Phase I/II Clinical Trial for the Evaluation of Bortezomib within the Reduced Intensity Conditioning Regimen (RIC) and Post-Allogeneic Transplantation As Gvhd Prophylaxis Among High-Risk Myeloma Patients. EudraCT: 2005â€“004858-27. Blood, 2011, 118, 3025-3025.	1.4	0
1029	High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM). Blood, 2011, 118, 630-630.	1.4	0
1030	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. Blood, 2011, 118, 3989-3989.	1.4	0
1031	6q Deletion Helps in the Discrimination Between Symptomatic Waldenstroïm's Macroglobulinemia and Asymptomatic Forms of IgM Monoclonal Gammopathies. Blood, 2012, 120, 4566-4566.	1.4	0
1032	Transcriptome Analysis Reveals Molecular Profiles Associated with Evolving Steps of Monoclonal Gammopathies.. Blood, 2012, 120, 2914-2914.	1.4	0
1033	Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC). Blood, 2012, 120, 3949-3949.	1.4	0
1034	Multiparameter Flow Cytometry (MFC) for Identification of the Waldenstroïm's Clone in IgM MGUS and Waldenstrom's Macroglobulinemia (WM): New Criteria for Differential Diagnosis and Risk Stratification. Blood, 2012, 120, 936-936.	1.4	0
1035	Phenotypic, Functional and Circadian Characterization of Peripheral Blood (PB) Multiple Myeloma (MM) Circulating Tumor Cells (CTCs). Blood, 2012, 120, 726-726.	1.4	0
1036	Genomic Comparison Of Clonal B-Cells In Waldenstrom Macroglobulinemia (WM) Versus IgM MGUS. Blood, 2013, 122, 400-400.	1.4	0
1037	Phenotypic Identification Of Subclones In Multiple Myeloma With Different Genomic Profile, Clonogenic Potential and Drug Sensitivity. Blood, 2013, 122, 531-531.	1.4	0
1038	Minimal Residual Disease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia. Blood, 2013, 122, 2576-2576.	1.4	0
1039	Phenotypic, Transcriptomic and Genomic Characterization Of Clonal Plasma Cells (PCs) From Newly Diagnosed Patients With Light Chain Amyloidosis (AL). Blood, 2013, 122, 1841-1841.	1.4	0
1040	Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis. Blood, 2013, 122, 4611-4611.	1.4	0
1041	Defects In DNA Double-Strand Break Repair and Increased Alternative Non-Homologous End Joining Pathways In Multiple Myeloma: Implications For Genome Stability. Blood, 2013, 122, 4882-4882.	1.4	0
1042	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	1.4	0
1043	Phenotypic and Genomic Analysis Of Multiple Myeloma (MM) Minimal Residual Disease (MRD) Clonal Plasma Cells (PCs). Blood, 2013, 122, 402-402.	1.4	0
1044	Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients. Blood, 2013, 122, 1848-1848.	1.4	0

#	ARTICLE	IF	CITATIONS
1045	Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CYCLO-LEN-DEX) for Previously Untreated Patients with Light-Chain Amyloidosis (AL). Blood, 2014, 124, 2135-2135.	1.4	0
1046	Intracлонаl Heterogeneity Associates with Clonal Stability in Multiple Myeloma. Blood, 2014, 124, 3412-3412.	1.4	0
1047	Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens. Blood, 2014, 124, 2108-2108.	1.4	0
1048	Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial. Blood, 2015, 126, 4504-4504.	1.4	0
1049	Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 2963-2963.	1.4	0
1050	Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment. Blood, 2015, 126, 4230-4230.	1.4	0
1051	Simplified in-House Deep Sequencing Method of Immunoglobulin Genes for Minimal Residual Disease Quantification and Risk Stratification in Multiple Myeloma. Blood, 2015, 126, 2972-2972.	1.4	0
1052	Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. Blood, 2015, 126, 2955-2955.	1.4	0
1053	Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial. Blood, 2016, 128, 2078-2078.	1.4	0
1054	Whole-Genome Analysis of the Chromatin Structure in Multiple Myeloma. Blood, 2016, 128, 118-118.	1.4	0
1055	Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial. Blood, 2018, 132, 474-474.	1.4	0
1056	Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development. Blood, 2018, 132, 188-188.	1.4	0
1057	Genetic Profiling and Novel Recurrent Chromosomal Alterations in Patients with Light Chain Amyloidosis. Blood, 2018, 132, 4488-4488.	1.4	0
1058	Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM). Blood, 2018, 132, 3550-3550.	1.4	0
1059	Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor. Blood, 2018, 132, 4503-4503.	1.4	0
1060	Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM). Blood, 2018, 132, 3170-3170.	1.4	0
1061	Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials. Blood, 2018, 132, 1964-1964.	1.4	0
1062	PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (Dâ€¦RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK. HemaSphere, 2019, 3, 247-248.	2.7	0

#	ARTICLE	IF	CITATIONS
1063	Lncrnas As New Partners of Novel Chimeric Transcripts in Multiple Myeloma. Blood, 2019, 134, 4356-4356.	1.4	0
1064	Computational Systems Biology Models for the Identification of Metabolic Vulnerabilities in Multiple Myeloma. Blood, 2019, 134, 3084-3084.	1.4	0
1065	A Computational Based Approach for Identification and Validation of Gene Mutations As Surrogate Markers of Gene Essentiality in Acute Myeloid Leukemia. Blood, 2019, 134, 1414-1414.	1.4	0
1066	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM). Blood, 2021, 138, 1596-1596.	1.4	0
1067	Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. Blood, 2021, 138, 5031-5031.	1.4	0
1068	Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Patterns from Dysplasia to Acute Myeloid Leukemia (AML). Blood, 2021, 138, 520-520.	1.4	0